{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:42:04Z","timestamp":1792093324422,"version":"4.4.0"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:00:00Z","timestamp":1774051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","award":["PhD fellowship DFA\/BD\/8167\/2020"],"award-info":[{"award-number":["PhD fellowship DFA\/BD\/8167\/2020"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","award":["iNOVA4Health \u2013 Programme in Translational Medicine (UID\/04462)"],"award-info":[{"award-number":["iNOVA4Health \u2013 Programme in Translational Medicine (UID\/04462)"]}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"crossref","award":["Project \u201cPROMETEUS\u201d, grant 823780"],"award-info":[{"award-number":["Project \u201cPROMETEUS\u201d, grant 823780"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"crossref","award":["Project \u201ceZVac\u201d, grant LISBOA2030-FEDER-00754700"],"award-info":[{"award-number":["Project \u201ceZVac\u201d, grant LISBOA2030-FEDER-00754700"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"DOI":"10.1186\/s12985-026-03130-4","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T07:54:47Z","timestamp":1774079687000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ferritin nanoparticles displaying rift valley fever virus glycoprotein elicit potent dendritic cell activation in vitro"],"prefix":"10.1186","volume":"23","author":[{"given":"Margarida Q.","family":"Rodrigues","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00eas","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00e1dia","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula M.","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ant\u00f3nio","family":"Rold\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,21]]},"reference":[{"key":"3130_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2478\/jvetres-2021-0009","volume":"65","author":"M Kwa\u015bnik","year":"2021","unstructured":"Kwa\u015bnik M, et al. Rift Valley Fever \u2013 a Growing Threat To Humans and Animals. J Vet Res. 2021;65:7\u201314.","journal-title":"J Vet Res"},{"key":"3130_CR2","doi-asserted-by":"publisher","first-page":"e014737","DOI":"10.1136\/bmjgh-2023-014737","volume":"9","author":"S Situma","year":"2024","unstructured":"Situma S, et al. Widening geographic range of Rift Valley fever disease clusters associated with climate change in East Africa. BMJ Glob Health. 2024;9:e014737.","journal-title":"BMJ Glob Health"},{"key":"3130_CR3","doi-asserted-by":"publisher","first-page":"883","DOI":"10.2460\/javma.234.7.883","volume":"234","author":"BH Bird","year":"2009","unstructured":"Bird BH, et al. Rift Valley fever virus. J Am Vet Med Assoc. 2009;234:883\u201393.","journal-title":"J Am Vet Med Assoc"},{"key":"3130_CR4","doi-asserted-by":"publisher","first-page":"100035","DOI":"10.1016\/j.ijidoh.2024.100035","volume":"4","author":"E Remera","year":"2024","unstructured":"Remera E, et al. Emergence of the first molecularly confirmed outbreak of Rift Valley fever among humans in Rwanda, calls for institutionalizing the One Health strategy. IJID One Health. 2024;4:100035.","journal-title":"IJID One Health"},{"key":"3130_CR5","unstructured":"Rift Valley fever- Mauritania and Senegal[Online]. Available: https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/2025-DON584. [Accessed: 14-Jan-2026]."},{"key":"3130_CR6","doi-asserted-by":"publisher","first-page":"e002694","DOI":"10.1136\/bmjgh-2020-002694","volume":"5","author":"V Petrova","year":"2020","unstructured":"Petrova V, et al. Rift valley fever: diagnostic challenges and investment needs for vaccine development. BMJ Glob Health. 2020;5:e002694.","journal-title":"BMJ Glob Health"},{"key":"3130_CR7","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0264-410X(99)00218-2","volume":"18","author":"PR Pittman","year":"1999","unstructured":"Pittman PR, et al. Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year experience. Vaccine. 1999;18:181\u20139.","journal-title":"Vaccine"},{"key":"3130_CR8","doi-asserted-by":"publisher","first-page":"3222","DOI":"10.1016\/j.vaccine.2011.02.037","volume":"29","author":"JM Rusnak","year":"2011","unstructured":"Rusnak JM, et al. Immunogenicity and safety of an inactivated Rift Valley fever vaccine in a 19-year study. Vaccine. 2011;29:3222\u20139.","journal-title":"Vaccine"},{"key":"3130_CR9","doi-asserted-by":"publisher","first-page":"5771","DOI":"10.1016\/j.vaccine.2011.05.055","volume":"29","author":"B von Teichman","year":"2011","unstructured":"von Teichman B, et al. Safety and efficacy of Rift Valley fever Smithburn and Clone 13 vaccines in calves. Vaccine. 2011;29:5771\u20137.","journal-title":"Vaccine"},{"key":"3130_CR10","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.vaccine.2015.11.078","volume":"34","author":"PR Pittman","year":"2016","unstructured":"Pittman PR, et al. Rift Valley Fever MP-12 Vaccine Phase 2 Clinical Trial: Safety, Immunogenicity, and Genetic Characterization of Virus Isolates. Vaccine. 2016;34:523\u201330.","journal-title":"Vaccine"},{"key":"3130_CR11","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S1473-3099(23)00068-3","volume":"23","author":"D Jenkin","year":"2023","unstructured":"Jenkin D, et al. Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley Fever in adults: an open-label, non-randomised, first-in-human phase 1 clinical trial. Lancet Infect Dis. 2023;23:956\u201364.","journal-title":"Lancet Infect Dis"},{"key":"3130_CR12","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1080\/21645515.2019.1627820","volume":"15","author":"J Ma","year":"2019","unstructured":"Ma J, et al. In vitro and in vivo efficacy of a Rift Valley fever virus vaccine based on pseudovirus. Hum Vaccines Immunother. 2019;15:2286\u201394.","journal-title":"Hum Vaccines Immunother"},{"key":"3130_CR13","doi-asserted-by":"publisher","first-page":"e2309","DOI":"10.1371\/journal.pntd.0002309","volume":"7","author":"E L\u00f3pez-Gil","year":"2013","unstructured":"L\u00f3pez-Gil E, et al. A single immunization with MVA expressing GnGc glycoproteins promotes epitope-specific CD8+-T cell activation and protects immune-competent mice against a lethal RVFV infection. PLoS Negl Trop Dis. 2013;7:e2309.","journal-title":"PLoS Negl Trop Dis"},{"key":"3130_CR14","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.3390\/vaccines10111794","volume":"10","author":"PK Kitandwe","year":"2022","unstructured":"Kitandwe PK, et al. An Overview of Rift Valley Fever Vaccine Development Strategies. Vaccines. 2022;10:1794.","journal-title":"Vaccines"},{"key":"3130_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-023-00769-w","volume":"8","author":"C Alkan","year":"2023","unstructured":"Alkan C, et al. Advancements in Rift Valley fever vaccines: a historical overview and prospects for next generation candidates. Npj Vaccines. 2023;8:1\u201316.","journal-title":"Npj Vaccines"},{"key":"3130_CR16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3389\/fcimb.2013.00013","volume":"3","author":"AE Gregory","year":"2013","unstructured":"Gregory AE, et al. Vaccine delivery using nanoparticles. Front Cell Infect Microbiol. 2013;3:13.","journal-title":"Front Cell Infect Microbiol"},{"key":"3130_CR17","doi-asserted-by":"publisher","first-page":"244","DOI":"10.7150\/ntno.19796","volume":"1","author":"S Chattopadhyay","year":"2017","unstructured":"Chattopadhyay S, et al. Nanoparticle Vaccines Adopting Virus-like Features for Enhanced Immune Potentiation. Nanotheranostics. 2017;1:244\u201360.","journal-title":"Nanotheranostics"},{"key":"3130_CR18","doi-asserted-by":"publisher","first-page":"607945","DOI":"10.3389\/fimmu.2020.607945","volume":"11","author":"MV Baranov","year":"2020","unstructured":"Baranov MV, et al. Modulation of Immune Responses by Particle Size and Shape. Front Immunol. 2020;11:607945.","journal-title":"Front Immunol"},{"key":"3130_CR19","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1038\/nmat3775","volume":"12","author":"DJ Irvine","year":"2013","unstructured":"Irvine DJ, et al. Engineering synthetic vaccines using cues from natural immunity. Nat Mater. 2013;12:978\u201390.","journal-title":"Nat Mater"},{"key":"3130_CR20","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.immuni.2018.08.012","volume":"49","author":"S Hong","year":"2018","unstructured":"Hong S, et al. B Cells Are the Dominant Antigen-Presenting Cells that Activate Naive CD4\u2009+\u2009T Cells upon Immunization with a Virus-Derived Nanoparticle Antigen. Immunity. 2018;49:695\u2013e7084.","journal-title":"Immunity"},{"key":"3130_CR21","first-page":"107","volume":"2","author":"A Monie","year":"2008","unstructured":"Monie A, et al. Cervarix\u2122: a vaccine for the prevention of HPV 16, 18-associated cervical cancer. Biol Targets Ther. 2008;2:107\u201313.","journal-title":"Biol Targets Ther"},{"key":"3130_CR22","doi-asserted-by":"publisher","first-page":"e83431","DOI":"10.1371\/journal.pone.0083431","volume":"8","author":"J Luna","year":"2013","unstructured":"Luna J, et al. Long-Term Follow-up Observation of the Safety, Immunogenicity, and Effectiveness of Gardasil\u2122 in Adult Women. PLoS ONE. 2013;8:e83431.","journal-title":"PLoS ONE"},{"key":"3130_CR23","doi-asserted-by":"publisher","first-page":"127987","DOI":"10.1016\/j.vaccine.2025.127987","volume":"69","author":"J Raupach","year":"2026","unstructured":"Raupach J, et al. Comparative analysis of a flexible novel vaccine platform based on cell permeable chimeric HBV capsids for mucosal vaccination. Vaccine. 2026;69:127987.","journal-title":"Vaccine"},{"key":"3130_CR24","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1021\/acschembio.5c00700","volume":"20","author":"HS Martin","year":"2025","unstructured":"Martin HS, et al. Engineered MS2 Virus Capsids for Cellular Display of Peptide Antigens. ACS Chem Biol. 2025;20:2943\u201354.","journal-title":"ACS Chem Biol"},{"key":"3130_CR25","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.cell.2020.10.043","volume":"183","author":"AC Walls","year":"2020","unstructured":"Walls AC, et al. Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2. Cell. 2020;183:1367\u2013e138217.","journal-title":"Cell"},{"key":"3130_CR26","doi-asserted-by":"publisher","first-page":"28295","DOI":"10.1021\/acsnano.5c06081","volume":"19","author":"J Joseph","year":"2025","unstructured":"Joseph J, et al. Lumazine Synthase Nanoparticles as a Versatile Platform for Multivalent Antigen Presentation and Cross-Protective Coronavirus Vaccines. ACS Nano. 2025;19:28295\u2013314.","journal-title":"ACS Nano"},{"key":"3130_CR27","doi-asserted-by":"publisher","first-page":"143912","DOI":"10.1016\/j.ijbiomac.2025.143912","volume":"311","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, et al. Encapsulin nanoparticle-conjugated p54 protein boosts immune responses against African swine fever virus. Int J Biol Macromol. 2025;311:143912.","journal-title":"Int J Biol Macromol"},{"key":"3130_CR28","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.3390\/pharmaceutics13101621","volume":"13","author":"MQ Rodrigues","year":"2021","unstructured":"Rodrigues MQ, et al. Functionalizing Ferritin Nanoparticles for Vaccine Development. Pharmaceutics. 2021;13:1621.","journal-title":"Pharmaceutics"},{"key":"3130_CR29","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.vaccine.2013.11.069","volume":"32","author":"L Zhao","year":"2014","unstructured":"Zhao L, et al. Nanoparticle vaccines. Vaccine. 2014;32:327\u201337.","journal-title":"Vaccine"},{"key":"3130_CR30","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/nature12202","volume":"499","author":"M Kanekiyo","year":"2013","unstructured":"Kanekiyo M, et al. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature. 2013;499:102\u20136.","journal-title":"Nature"},{"key":"3130_CR31","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/nm.3927","volume":"21","author":"HM Yassine","year":"2015","unstructured":"Yassine HM, et al. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat Med. 2015;21:1065\u201370.","journal-title":"Nat Med"},{"key":"3130_CR32","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.cell.2015.07.043","volume":"162","author":"M Kanekiyo","year":"2015","unstructured":"Kanekiyo M, et al. Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site. Cell. 2015;162:1090\u2013100.","journal-title":"Cell"},{"key":"3130_CR33","doi-asserted-by":"publisher","first-page":"110143","DOI":"10.1016\/j.celrep.2021.110143","volume":"37","author":"MG Joyce","year":"2021","unstructured":"Joyce MG, et al. SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity. Cell Rep. 2021;37:110143.","journal-title":"Cell Rep"},{"key":"3130_CR34","doi-asserted-by":"publisher","first-page":"eaay7199","DOI":"10.1126\/science.aay7199","volume":"366","author":"KO Saunders","year":"2019","unstructured":"Saunders KO, et al. Targeted selection of HIV-specific antibody mutations by engineering B cell maturation. Science. 2019;366:eaay7199.","journal-title":"Science"},{"key":"3130_CR35","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/s41591-021-01660-8","volume":"28","author":"KV Houser","year":"2022","unstructured":"Houser KV, et al. Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial. Nat Med. 2022;28:383\u201391.","journal-title":"Nat Med"},{"key":"3130_CR36","doi-asserted-by":"publisher","first-page":"eade4976","DOI":"10.1126\/scitranslmed.ade4976","volume":"15","author":"SF Andrews","year":"2023","unstructured":"Andrews SF, et al. An influenza H1 hemagglutinin stem-only immunogen elicits a broadly cross-reactive B cell response in humans. Sci Transl Med. 2023;15:eade4976.","journal-title":"Sci Transl Med"},{"key":"3130_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-024-00959-0","volume":"9","author":"JP Casazza","year":"2024","unstructured":"Casazza JP, et al. Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine. Npj Vaccines. 2024;9:1\u201310.","journal-title":"Npj Vaccines"},{"key":"3130_CR38","doi-asserted-by":"publisher","first-page":"e581","DOI":"10.1016\/S2666-5247(23)00410-X","volume":"5","author":"BLO Shepherd","year":"2024","unstructured":"Shepherd BLO, et al. SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial. Lancet Microbe. 2024;5:e581\u201393.","journal-title":"Lancet Microbe"},{"key":"3130_CR39","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1189\/jlb.0208092","volume":"84","author":"SJAM Santegoets","year":"2008","unstructured":"Santegoets SJAM, et al. Human dendritic cell line models for DC differentiation and clinical DC vaccination studies. J Leukoc Biol. 2008;84:1364\u201373.","journal-title":"J Leukoc Biol"},{"key":"3130_CR40","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1111\/j.1365-2567.2005.02274.x","volume":"117","author":"K Larsson","year":"2006","unstructured":"Larsson K, et al. Functional and transcriptional profiling of MUTZ-3, a myeloid cell line acting as a model for dendritic cells. Immunology. 2006;117:156\u201366.","journal-title":"Immunology"},{"key":"3130_CR41","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.imbio.2007.06.001","volume":"213","author":"I Teobald","year":"2008","unstructured":"Teobald I, et al. Phenotypic and functional differentiation of KG-1 into dendritic-like cells. Immunobiology. 2008;213:75\u201386.","journal-title":"Immunobiology"},{"key":"3130_CR42","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.3390\/ijms24021452","volume":"24","author":"JM H\u00f6lken","year":"2023","unstructured":"H\u00f6lken JM, Teusch N. The Monocytic Cell Line THP-1 as a Validated and Robust Surrogate Model for Human Dendritic Cells. Int J Mol Sci. 2023;24:1452.","journal-title":"Int J Mol Sci"},{"key":"3130_CR43","doi-asserted-by":"publisher","first-page":"101669","DOI":"10.1016\/j.isci.2020.101669","volume":"23","author":"D Wright","year":"2020","unstructured":"Wright D, et al. Naturally Acquired Rift Valley Fever Virus Neutralizing Antibodies Predominantly Target the Gn Glycoprotein. iScience. 2020;23:101669.","journal-title":"iScience"},{"key":"3130_CR44","doi-asserted-by":"publisher","first-page":"D678","DOI":"10.1093\/nar\/gkac1003","volume":"51","author":"RD Olson","year":"2023","unstructured":"Olson RD, et al. Introducing the Bacterial and Viral Bioinformatics Resource Center (BV-BRC): a resource combining PATRIC, IRD and ViPR. Nucleic Acids Res. 2023;51:D678\u201389.","journal-title":"Nucleic Acids Res"},{"key":"3130_CR45","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3390\/vaccines9030301","volume":"9","author":"PJ Wichgers Schreur","year":"2021","unstructured":"Wichgers Schreur PJ, et al. Vaccine Efficacy of Self-Assembled Multimeric Protein Scaffold Particles Displaying the Glycoprotein Gn Head Domain of Rift Valley Fever Virus. Vaccines. 2021;9:301.","journal-title":"Vaccines"},{"key":"3130_CR46","doi-asserted-by":"publisher","first-page":"W521","DOI":"10.1093\/nar\/gkae241","volume":"52","author":"F Madeira","year":"2024","unstructured":"Madeira F, et al. The EMBL-EBI Job Dispatcher sequence analysis tools framework in 2024. Nucleic Acids Res. 2024;52:W521\u20135.","journal-title":"Nucleic Acids Res"},{"key":"3130_CR47","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13036-025-00550-8","volume":"19","author":"MQ Rodrigues","year":"2025","unstructured":"Rodrigues MQ, et al. Baculovirus-mediated production and purification of ferritin nanoparticles for rift valley fever vaccine development. J Biol Eng. 2025;19:75.","journal-title":"J Biol Eng"},{"key":"3130_CR48","doi-asserted-by":"publisher","first-page":"40803","DOI":"10.1038\/s41598-025-24514-6","volume":"15","author":"MQ Rodrigues","year":"2025","unstructured":"Rodrigues MQ, et al. Site-directed tyrosinase conjugation on engineered ferritin retains immune recognition. Sci Rep. 2025;15:40803.","journal-title":"Sci Rep"},{"key":"3130_CR49","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nmeth.4169","volume":"14","author":"A Punjani","year":"2017","unstructured":"Punjani A, et al. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat Methods. 2017;14:290\u20136.","journal-title":"Nat Methods"},{"key":"3130_CR50","doi-asserted-by":"publisher","first-page":"e4792","DOI":"10.1002\/pro.4792","volume":"32","author":"EC Meng","year":"2023","unstructured":"Meng EC, et al. UCSF ChimeraX: Tools for structure building and analysis. Protein Sci. 2023;32:e4792.","journal-title":"Protein Sci"},{"key":"3130_CR51","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1111\/sji.12371","volume":"82","author":"L Czernek","year":"2015","unstructured":"Czernek L, et al. The Uptake of Extracellular Vesicles is Affected by the Differentiation Status of Myeloid Cells. Scand J Immunol. 2015;82:506\u201314.","journal-title":"Scand J Immunol"},{"key":"3130_CR52","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1093\/intimm\/14.5.493","volume":"14","author":"EB Olasz","year":"2002","unstructured":"Olasz EB, et al. Soluble proteins and haptens on bone marrow-derived dendritic cells are presented to host CD4 T cells in an MHC-restricted manner. Int Immunol. 2002;14:493\u2013502.","journal-title":"Int Immunol"},{"key":"3130_CR53","doi-asserted-by":"publisher","first-page":"e006778","DOI":"10.1161\/JAHA.117.006778","volume":"6","author":"M Rahman","year":"2017","unstructured":"Rahman M, et al. Induction of Dendritic Cell\u2013Mediated Activation of T Cells From Atherosclerotic Plaques by Human Heat Shock Protein 60. J Am Heart Assoc Cardiovasc Cerebrovasc Dis. 2017;6:e006778.","journal-title":"J Am Heart Assoc Cardiovasc Cerebrovasc Dis"},{"key":"3130_CR54","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1186\/s13071-025-07074-6","volume":"18","author":"X Yuan","year":"2025","unstructured":"Yuan X, et al. Regulation of dendritic cell immune function and maturation by the recombinant antigen p53 of Trichinella spiralis. Parasit Vectors. 2025;18:423.","journal-title":"Parasit Vectors"},{"key":"3130_CR55","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1186\/s12967-024-05368-4","volume":"22","author":"P Po\u017eenel","year":"2024","unstructured":"Po\u017eenel P, et al. Factor of time in dendritic cell (DC) maturation: short-term activation of DCs significantly improves type 1 cytokine production and T cell responses. J Transl Med. 2024;22:541.","journal-title":"J Transl Med"},{"key":"3130_CR56","doi-asserted-by":"publisher","first-page":"5634","DOI":"10.1038\/s41596-021-00628-9","volume":"16","author":"Z Du","year":"2021","unstructured":"Du Z, et al. The trRosetta server for fast and accurate protein structure prediction. Nat Protoc. 2021;16:5634\u201351.","journal-title":"Nat Protoc"},{"key":"3130_CR57","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/s43588-022-00373-3","volume":"2","author":"W Wang","year":"2022","unstructured":"Wang W, et al. Single-sequence protein structure prediction using supervised transformer protein language models. Nat Comput Sci. 2022;2:804\u201314.","journal-title":"Nat Comput Sci"},{"key":"3130_CR58","doi-asserted-by":"publisher","first-page":"2102592","DOI":"10.1002\/advs.202102592","volume":"8","author":"H Su","year":"2021","unstructured":"Su H, et al. Improved Protein Structure Prediction Using a New Multi-Scale Network and Homologous Templates. Adv Sci. 2021;8:2102592.","journal-title":"Adv Sci"},{"key":"3130_CR59","unstructured":"Schr\u00f6dinger L. (2015) The PyMOL Molecular Graphics System."},{"key":"3130_CR60","doi-asserted-by":"crossref","unstructured":"Kim KH et al. (2009) Structural basis for the iron uptake mechanism of Helicobacter pylori ferritin. RCSB PDB. [Online]. Available: https:\/\/www.rcsb.org\/structure\/3BVE","DOI":"10.2210\/pdb3bvl\/pdb"},{"key":"3130_CR61","doi-asserted-by":"crossref","unstructured":"Wu Y et al. (2017) The structure of RVFV Gn head domain. RCSB PDB. [Online]. Available: https:\/\/www.rcsb.org\/structure\/5Y0W","DOI":"10.2210\/pdb5y0w\/pdb"},{"key":"3130_CR62","doi-asserted-by":"publisher","first-page":"E7564","DOI":"10.1073\/pnas.1705176114","volume":"114","author":"Y Wu","year":"2017","unstructured":"Wu Y, et al. Structures of phlebovirus glycoprotein Gn and identification of a neutralizing antibody epitope. Proc Natl Acad Sci U S A. 2017;114:E7564\u201373.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3130_CR63","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.acthis.2014.04.006","volume":"116","author":"A Chilumuri","year":"2014","unstructured":"Chilumuri A, et al. Immunocytochemical staining of endogenous nuclear proteins with the HIS-1 anti-poly-histidine monoclonal antibody: a potential source of error in His-tagged protein detection. Acta Histochem. 2014;116:1022\u20138.","journal-title":"Acta Histochem"},{"key":"3130_CR64","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.intimp.2014.08.002","volume":"23","author":"W Chanput","year":"2014","unstructured":"Chanput W, et al. THP-1 cell line: An in vitro cell model for immune modulation approach. Int Immunopharmacol. 2014;23:37\u201345.","journal-title":"Int Immunopharmacol"},{"key":"3130_CR65","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.4049\/jimmunol.172.4.2307","volume":"172","author":"SH Jackson","year":"2004","unstructured":"Jackson SH, et al. Dendritic Cell Maturation Requires STAT1 and Is under Feedback Regulation by Suppressors of Cytokine Signaling. J Immunol. 2004;172:2307\u201315.","journal-title":"J Immunol"},{"key":"3130_CR66","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1146\/annurev.biochem.71.110601.135414","volume":"71","author":"CRH Raetz","year":"2002","unstructured":"Raetz CRH, Whitfield C. Lipopolysaccharide Endotoxins. Annu Rev Biochem. 2002;71:635\u2013700.","journal-title":"Annu Rev Biochem"},{"key":"3130_CR67","first-page":"1","volume":"6","author":"X Hu","year":"2021","unstructured":"Hu X, et al. The JAK\/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021;6:1\u201333.","journal-title":"Signal Transduct Target Ther"},{"key":"3130_CR68","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1084\/jem.20051395","volume":"202","author":"C Asselin-Paturel","year":"2005","unstructured":"Asselin-Paturel C, Trinchieri G. Production of type I interferons. J Exp Med. 2005;202:461\u20135.","journal-title":"J Exp Med"},{"key":"3130_CR69","doi-asserted-by":"publisher","first-page":"872155","DOI":"10.3389\/fimmu.2022.872155","volume":"13","author":"D Boraschi","year":"2022","unstructured":"Boraschi D. What Is IL-1 for? The Functions of Interleukin-1 Across Evolution. Front Immunol. 2022;13:872155.","journal-title":"Front Immunol"},{"key":"3130_CR70","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/JLB.3MR0621-616RR","volume":"111","author":"Y-D Xu","year":"2022","unstructured":"Xu Y-D, et al. Role of IL-6 in dendritic cell functions. J Leukoc Biol. 2022;111:695\u2013709.","journal-title":"J Leukoc Biol"},{"key":"3130_CR71","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/eji.1830260323","volume":"26","author":"C Heufler","year":"1996","unstructured":"Heufler C, et al. Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon-\u03b3 production by T helper 1 cells. Eur J Immunol. 1996;26:659\u201368.","journal-title":"Eur J Immunol"},{"key":"3130_CR72","doi-asserted-by":"crossref","unstructured":"Trevejo JM et al. (2001) TNF-\u03b1-dependent maturation of local dendritic cells is critical for activating the adaptive immune response to virus infection. Proc. Natl. Acad. Sci. 98, 12162\u201312167.","DOI":"10.1073\/pnas.211423598"},{"key":"3130_CR73","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.4049\/jimmunol.179.3.1449","volume":"179","author":"S Iwamoto","year":"2007","unstructured":"Iwamoto S, et al. TNF-\u03b1 Drives Human CD14\u2009+\u2009Monocytes to Differentiate into CD70\u2009+\u2009Dendritic Cells Evoking Th1 and Th17 Responses. J Immunol. 2007;179:1449\u201357.","journal-title":"J Immunol"},{"key":"3130_CR74","doi-asserted-by":"publisher","first-page":"785","DOI":"10.4049\/jimmunol.1901358","volume":"206","author":"A Psarras","year":"2021","unstructured":"Psarras A, et al. TNF-\u03b1 Regulates Human Plasmacytoid Dendritic Cells by Suppressing IFN-\u03b1 Production and Enhancing T Cell Activation. J Immunol. 2021;206:785\u201396.","journal-title":"J Immunol"},{"key":"3130_CR75","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.immuni.2012.05.008","volume":"36","author":"A Zlotnik","year":"2012","unstructured":"Zlotnik A, Yoshie O. The chemokine superfamily revisited. Immunity. 2012;36:705\u201316.","journal-title":"Immunity"},{"key":"3130_CR76","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1007\/s00262-008-0474-9","volume":"57","author":"NA Sheikh","year":"2008","unstructured":"Sheikh NA, Jones LA. CD54 is a surrogate marker of antigen presenting cell activation. Cancer Immunol Immunother CII. 2008;57:1381\u201390.","journal-title":"Cancer Immunol Immunother CII"},{"key":"3130_CR77","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1042\/BJ20040741","volume":"385","author":"W Cao","year":"2005","unstructured":"Cao W, et al. CD83 is preformed inside monocytes, macrophages and dendritic cells, but it is only stably expressed on activated dendritic cells. Biochem J. 2005;385:85\u201393.","journal-title":"Biochem J"},{"key":"3130_CR78","doi-asserted-by":"publisher","first-page":"9159","DOI":"10.1128\/JVI.00422-06","volume":"80","author":"S Fuse","year":"2006","unstructured":"Fuse S, et al. CD80 and CD86 Control Antiviral CD8\u2009+\u2009T-Cell Function and Immune Surveillance of Murine Gammaherpesvirus 68. J Virol. 2006;80:9159\u201370.","journal-title":"J Virol"},{"key":"3130_CR79","doi-asserted-by":"publisher","first-page":"5509","DOI":"10.3390\/ijms25105509","volume":"25","author":"L Ye","year":"2024","unstructured":"Ye L, et al. Profiling of Early Immune Responses to Vaccination Using THP-1-Derived Dendritic Cells. Int J Mol Sci. 2024;25:5509.","journal-title":"Int J Mol Sci"},{"key":"3130_CR80","doi-asserted-by":"publisher","first-page":"0","DOI":"10.23880\/act-16000320","volume":"9","author":"C Ps","year":"2024","unstructured":"Ps C, et al. THP-1-Derived Dendritic Cells: A Rapid and Reproducible In VitroModel for Phagocytosis Assays Involving Tumor Cells. Adv Clin Toxicol. 2024;9:0\u20130.","journal-title":"Adv Clin Toxicol"},{"key":"3130_CR81","doi-asserted-by":"publisher","first-page":"612397","DOI":"10.3389\/fnut.2020.612397","volume":"7","author":"Y Deng","year":"2020","unstructured":"Deng Y, et al. A THP-1 Cell Line-Based Exploration of Immune Responses Toward Heat-Treated BLG. Front Nutr. 2020;7:612397.","journal-title":"Front Nutr"},{"key":"3130_CR82","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.intimp.2018.05.013","volume":"62","author":"L Li","year":"2018","unstructured":"Li L, et al. Activation profile of THP-1 derived dendritic cells stimulated by allergen Mal f 1 beyond its IgE-binding ability. Int Immunopharmacol. 2018;62:139\u201346.","journal-title":"Int Immunopharmacol"},{"key":"3130_CR83","doi-asserted-by":"publisher","first-page":"113147","DOI":"10.1016\/j.jim.2021.113147","volume":"498","author":"Y Wen","year":"2021","unstructured":"Wen Y, et al. Comparability study of monocyte derived dendritic cells, primary monocytes, and THP1 cells for innate immune responses. J Immunol Methods. 2021;498:113147.","journal-title":"J Immunol Methods"},{"key":"3130_CR84","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1007\/s00705-010-0768-z","volume":"155","author":"L Huhti","year":"2010","unstructured":"Huhti L, et al. A comparison of methods for purification and concentration of norovirus GII-4 capsid virus-like particles. Arch Virol. 2010;155:1855\u20138.","journal-title":"Arch Virol"},{"key":"3130_CR85","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1074\/jbc.M109.024612","volume":"285","author":"H Zheng","year":"2010","unstructured":"Zheng H, et al. Chaperokine function of recombinant Hsp72 produced in insect cells using a baculovirus expression system is retained. J Biol Chem. 2010;285:349\u201356.","journal-title":"J Biol Chem"},{"key":"3130_CR86","doi-asserted-by":"crossref","unstructured":"Zhang L et al. (2025) Cryo-EM structure of the Rift Valley fever virus envelope protein in complex with a potent neutralization antibody. Proc. Natl. Acad. Sci. 122, e2514862122.","DOI":"10.1073\/pnas.2514862122"},{"key":"3130_CR87","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/j.1600-065X.2010.00978.x","volume":"239","author":"MS Duthie","year":"2011","unstructured":"Duthie MS, et al. Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev. 2011;239:178\u201396.","journal-title":"Immunol Rev"},{"key":"3130_CR88","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1038\/s41590-022-01359-z","volume":"23","author":"AC Palin","year":"2022","unstructured":"Palin AC, et al. The Persistence of Memory: Defining, Engineering, and Measuring Vaccine Durability. Nat Immunol. 2022;23:1665\u20138.","journal-title":"Nat Immunol"},{"key":"3130_CR89","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.1016\/j.vaccine.2010.02.018","volume":"28","author":"G Lorenzo","year":"2010","unstructured":"Lorenzo G, et al. Protection against lethal Rift Valley fever virus (RVFV) infection in transgenic IFNAR\u2013\/\u2013 mice induced by different DNA vaccination regimens. Vaccine. 2010;28:2937\u201344.","journal-title":"Vaccine"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-026-03130-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-026-03130-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-026-03130-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T04:15:48Z","timestamp":1777436148000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12985-026-03130-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,21]]},"references-count":89,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3130"],"URL":"https:\/\/doi.org\/10.1186\/s12985-026-03130-4","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,21]]},"assertion":[{"value":"27 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"117"}}